Catalytic role of cytochrome P4502B6 in the N-demethylation of S- mephenytoin

Drug Metabolism and Disposition

Volumn 24, Issue 9, 1996, Pages 948-954

  Heyn, Heleen ^a   White, Rebecca B ^a   Stevens, Jeffrey C ^a,b  

^a Rhône Poulenc Rorer R and D ^*  (France)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COUMARIN; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; ENZYME INHIBITOR; MEPHENYTOIN; N DEMETHYLASE; NORMEPHENYTOIN; ORPHENADRINE; TROLEANDOMYCIN;

ARTICLE; DEMETHYLATION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; KINETICS; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY;

ANTIBODIES, MONOCLONAL; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; COUMARINS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; KINETICS; MEPHENYTOIN; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES, N-DEMETHYLATING; RECOMBINANT PROTEINS; TROLEANDOMYCIN;

EID: 0029833258     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. F. P. Guengerich: Human cytochrome P450 enzymes. Life Sci. 50, 1471-1478 (1992).
2. F. J. Gonzalez: The molecular biology of cytochrome P450s. Pharmacol. Rev. 40, 243-288 (1989).
3. S. A. Wrighton and J. C. Stevens: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22, 1-21 (1992).
4. C. C. Peck, R. Temple, and J. M. Collins: Understanding consequences of concurrent therapies. J.A.M.A. 269, 1550-1552 (1993).
5. S.-H. L. Chiu: The use of in vitro metabolism studies in the understanding of new drugs. J. Pharmacol. Toxicol. Methods 29, 77-83 (1993).
6. S. A. Wrighton, M. Vandenbranden, J. C. Stevens, L. A. Shipley, B. J. Ring, A. E. Rettie, and J. R. Cashman: In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab. Rev. 25, 453-484 (1993).
7. R. K. Lynn, J. E. Bauer, W. P. Gordon, R. G. Smith, D. Griffin, R. M. Thompson, R. Jenkins, and N. Gerber: Characterization of mephenytoin metabolites in human urine by gas chromatography. Drug Metab. Dispos. 7, 138-144 (1979).
8. A. Kupfer, G. M. Brilis, J. T. Watson, and T. M. Harris: A major pathway of mephenytoin metabolism in man. Aromatic hydroxylation to p-hydroxymephenytoin. Drug Metab. Dispos. 8, 1-4 (1980).
9. A. Kupfer and R. Preisig: Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol. 26, 753-759 (1984).
10. P. J. Wedlund, W. S. Aslanian, C. B. McAllister, G. R. Wilkinson, and R. A. Branch: Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin. Pharmacol. Ther. 36, 773-780 (1984).
11. S. A. Wrighton, J. C. Stevens, G. W. Becker, and M. VandenBranden: Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306, 240-245 (1993).
12. J. A. Goldstein, M. B. Faletto, M. Romkes-Sparks, T. Sullivan, S. Kitareewan, J. L. Raucy, J. M. Lasker, and B. I. Ghanayem: Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33, 1743-1752 (1994).
13. J. Pfister: Rapid, high-yield oxidation of Hantzch-type 1,4-dihydropyridines with ceric ammonium nitrate. Synthesis 8, 689-690 (1990).
14. P. P. Wang, P. Beaune, L. S. Kaminsky, G. A. Dannan, F. F. Kahzubari, D. Larrey, and F. P. Guengerich: Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. Biochemistry 22, 5375-5383 (1983).
15. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275 (1951).
16. T. Omura and R. Sato: The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370-2378 (1964).
17. M. Sattler, F. P. Guengerich, C.-H. Yun, U. Christians, and K.-F. Sewing: Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos. 20, 753-761 (1992).
18. R. Pearce, D. Greenway, and A. Parkinson: Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Arch. Biochem. Biophys. 298, 211-225 (1992).
19. J. T. M. Buters, C. D. Schiller, and R. C. Chou: A highly sensitive tool for the assay of cytochrome P450 enzyme activity in rat, dog and man: direct fluorescence monitoring of the deethylation of 7-ethoxy-4-trifluoromethyl-coumarin. Biochem. Pharmacol. 46, 1577-1584 (1993).
20. R. G. Knodell, S. D. Hall, G. R. Wilkinson, and F. P. Guengerich: Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J. Pharmacol. Exp. Ther. 241, 1112-1119 (1987).
21. U. T. Meier, T. Kronbach, and U. A. Meyer: Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Anal. Biochem. 151, 286-291 (1985).
22. T. Kronbach, D. Mathys, J. Gut, T. Catin, and U. A. Meyer: High performance liquid chromatographic analysis for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P450 isozymes of human liver. Anal. Biochem. 162, 24-32 (1987).
23. R. Peter, R. G. Bocker, P. H. Beaune, M. Iwasaki, F. P. Guengerich, and C. S. Yang: Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450IIE1. Chem. Res. Toxicol. 3, 566-573 (1990).
24. F. P. Guengerich, M. V. Martin, P. H. Beaune, P. Kremers, T. Wolff, and D. J. Waxman: Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261, 5051-5060 (1986).
25. D. J. Newton, R. W. Wang, and A. Y. H. Lu: Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
26. L. M. Forrester, C. J. Henderson, M. J. Glancey, D. J. Back, B. K. Park, S. E. Ball, N. R. Ketteringham, A. W. McLaren, J. S. Miles, P. Skett, and C. R. Wolf: Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem. J. 281, 359-368 (1992).
27. D. Pessayre, D. Larrey, J. Vitaux, P. Breil, J. Belghiti, and J. P. Benhamou: Formation of an inactive cytochrome P450 Fe(II)-metabolite complex after administration of troleandomycin in humans. Biochem. Phamacol. 31, 1699-1704 (1982).
28. G. F. Reidy, I. Mehta, and M. Murray: Inhibition of drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. Mol. Pharmacol. 35, 736-743 (1989).
29. T. Yasumori, L. Chen, K. Nagata, Y. Yamazoe, and R. Kato: Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). J. Pharmacol. Exp. Ther. 264, 89-94 (1993).
30. M. A. Lang, R. Juvonen, P. Jarvinen, P. Honkakoski, and H. Raunio. Mouse liver P450Coh: genetic regulation of the pyrazole-inducible enzyme and comparison with other P450 isoenzymes. Arch. Biochem. Biophys. 271, 139-148 (1989).
31. A. M. Ramming, H. V. Gelboin, T. Aoyama, F. J. Gonzalez, and G. D. McCoy: Nicotine metabolism by cDNA-expressed human cytochrome P-450s. Biochem. Arch. 8, 1-8 (1992).
32. M. T. Baker, M. J. Olson, Y. Wang, W. C. Ronnenberg, Jr., J. T. Johnson, and A. N. Brady: Isoflurane-chlorodifluoroethene interaction in human liver microsomes: role of cytochrome P4502B6 in potentiation of haloethene metabolism. Drug Metab. Dispos. 23, 60-64 (1995).
33. T. K. H. Chang, G. F. Weber, C. L. Crespi, and D. J. Waxman: Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53, 5629-5637 (1993).
34. T. Nakajima, E. Elovaara, F. J. Gonzalez, H. V. Gelboin, H. Vainio, and T. Aoyama: Characterization of the human P450 isozyme responsible for styrène metabolism. IARC Sci. Publ. 127, 101-108 (1993).
35. M. Mimura, T. Baba, H. Yamazaki, S. Ohmori, Y. Inui, F. J. Gonzalez, F. P. Guengerich, and T. Shimada: Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab. Dispos. 21, 1048-1056 (1993).